Zusammenfassung
Durch das humane Papillomavirus (HPV) induzierte Kopf-Hals-Karzinome unterscheiden sich signifikant von noxenbedingten Tumoren in dieser Region. Etwa 30–50% aller Oropharynxkarzinome werden mit dem HPV in Verbindung gebracht. Studien zeigen, dass die Inzidenz steigend ist. HPV-assoziierte Kopf-Hals-Karzinome haben im Gegensatz zu anderen, durch Noxen bedingten Tumoren eine deutlich bessere Prognose, welche sich durch ein erhöhtes Therapieansprechen erklären lässt. In diesem Zusammenhang wird vermutet, dass vor allem Patienten mit einer Genüberexpression immunologisch wirksamer Proteine in der Antigenpräsentation von einer kombinierten Radiochemotherapie profitieren. Demgegenüber scheint sich in einer aktuellen retrospektiven Studie der therapeutische Einsatz einer Radiotherapie in Kombination mit einer molekularen Targettherapie als vorteilig abzuzeichnen.
Abstract
HPV-positive head and neck carcinoma is significantly different than tobacco- and alcohol-induced cancer. Between 30% and 50% of oropharyngeal cancers are associated with human papillomavirus (HPV). Studies still show an increasing incidence. HPV-positive head and neck cancer patients have a better prognosis due to a better response to therapy. Especially patients with gene overexpression of immunological proteins in the antigen presentation are suggested to benefit from radiotherapy. A current retrospective study shows better outcomes for patients treated with radiotherapy in combination with biological targets compared to radiochemotherapy.
This is a preview of subscription content, log in via an institution to check access.
Literatur
Ang KK, Harris J, Wheeler R et al (2010) Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 363:24–35
Attner P (2011) Factors predicting survival outcomes for patients with HPV-positive base of tongue cancer. ASCO Meeting Abstracts 29:5575
Chaturvedi A, Engels E, Pfeiffer R et al (2011) Human papillomavirus (HPV) and rising oropharyngeal cancer incidence and survival in the United States. ASCO Meeting Abstracts 29:5529
Fakhry C, Westra WH, Li S et al (2008) Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 100:261–269
Knoedler M, Zakarneh A, Zimmermann U et al (2011) Effects of human papillomavirus (HPV) and other potential risk factors on survival in patients with oropharyngeal cancer. ASCO Meeting Abstracts 29:5577
Lowy DR, Munger K (2010) Prognostic implications of HPV in oropharyngeal cancer. N Engl J Med 363:82–84
Mannarini L, Kratochvil V, Calabrese L et al (2009) Human Papilloma Virus (HPV) in head and neck region: review of literature. Acta Otorhinolaryngol Ital 29:119–126
Marur S, D’souza G, Westra WH et al (2010) HPV-associated head and neck cancer: a virus-related cancer epidemic. Lancet Oncol 11:781–789
Pajares B, Trigo Perez JM, Toledo MD et al (2011) Human papillomavirus (HPV)-related head and neck squamous cell carcinoma (HNSCC) and outcome after treatment with epidermal growth factor receptor inhibitors (EGFR inhib) plus radiotherapy (RT) versus conventional chemotherapy (CT) plus RT. ASCO Meeting Abstracts 29:5528
Preuss SF, Klussmann JP, Semrau R et al (2011) Update on HPV-induced oropharyngeal cancer. HNO 59:1031–1038
Schwartz SM, Daling JR, Doody DR et al (1998) Oral cancer risk in relation to sexual history and evidence of human papillomavirus infection. J Natl Cancer Inst 90:1626–1636
Temam S, Kawaguchi H, El-Naggar AK et al (2007) Epidermal growth factor receptor copy number alterations correlate with poor clinical outcome in patients with head and neck squamous cancer. J Clin Oncol 25:2164–2170
Thibaudeau E, Soulieres D, Fortin B et al (2011) HPV prevalence and prognostic value in a prospective cohort of 255 patients with locally advanced squamous cell carcinoma of the head and neck treated with chemoradiation therapy at Centre Hospitalier de l’Universite de Montreal: a single-center experience. ASCO Meeting Abstracts 29:5574
Thibodeau BJ, Geddes TJ, Ahmed S et al (2011) Gene expression profiling predicts nonresponders to chemoradiation in HPV16-positive head and neck squamous cell carcinoma. ASCO Meeting Abstracts 29:5589
Tribius S, Ihloff AS, Rieckmann T et al (2011) Impact of HPV status on treatment of squamous cell cancer of the oropharynx: what we know and what we need to know. Cancer Lett 304:71–79
Weinberger PM, Yu Z, Haffty BG et al (2006) Molecular classification identifies a subset of human papillomavirus–associated oropharyngeal cancers with favorable prognosis. J Clin Oncol 24:736–747
Wittekindt C, Wagner S, Klussmann JP (2011) HPV-associated head and neck cancer. The basics of molecular and translational research. HNO 59:885–892
Interessenkonflikt
Der korrespondierende Autor weist auf folgende Beziehungen hin: Frau Kofler gibt an, dass kein Interessenkonflikt besteht. Prof. Dr. R. Knecht ist als wissenschaftlicher Berater für Merck Serono und Sanofi Aventis tätig.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kofler, B., Uecker, F., Muenscher, A. et al. Neue Aspekte HPV-positiver Kopf-Hals-Karzinome. HNO 60, 404–409 (2012). https://doi.org/10.1007/s00106-011-2465-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00106-011-2465-y
Schlüsselwörter
- Humanes Papillomavirus
- Plattenepithelkarzinom
- Oropharynxkarzinom
- Radiotherapie
- Molekulare Targettherapie